Intrinsiqq
CytoMed Therapeutics Ltd. logo

CytoMed Therapeutics Ltd.

GDTC

Compare
⚠ Showing the latest available close (Nov 16, 2026, 2 days ago). Our price provider hasn't published a newer EOD for this ticker yet. Price-dependent metrics (P/E, P/FCF, yield) may not reflect current market conditions.

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market CapSGD 11M
EPS-SGD 0.38
P/E-2.06
P/FCF-2.41
EV/EBITDA-2.12
FCF Yield–
Div. Yield–
Net Debt/FCF0.4x
CytoMed Therapeutics Ltd. intrinsic value
52-Week Range
$0.72$1.97

Profitability & Returns

Revenue (TTM)

SGD 324K

▲ +366.7% YoY

Net Income (TTM)

-SGD 4M

▼ -58.5% YoY

Op. Margin

-1307.60%

▲ +3196.7pp YoY

ROIC

-39.79%

▼ -16.5pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-SGD 4M

▼ -4.7% YoY

Op. Cash Flow (TTM)

-SGD 4M

▼ -36.4% YoY

Net Debt

-SGD 2M

Net Cash Position

Cash & Equiv.

SGD 2M

Continue Research

Peers

Biotechnology · Pick stocks to compare with GDTC

CompareIntrinsic value
IINNInspira Technologies Oxy B.H.N. Ltd.
$1.15-8.00%10
RDHLRedHill Biopharma Ltd. American
$0.36-3.73%10
ALNEV.XPARNeovacs S.A.
€0.07-0.87%40
XLS.XSWXXlife Sciences AG
€8.68-1.14%0
ALHYG.XPARHybrigenics SA
€0.01-6.67%15
ALOPM.XPAROncodesign Precision Medicine
€0.24-6.95%41
EVG.XLONEvgen Pharma PLC
£0.00-5.88%40
QLIFE.XSTOQlife Holding AB
€0.06-15.71%0

CytoMed Therapeutics (GDTC) in four numbers

Fair value (revenue)
$0.06
Price $0.77 is 1231% above it.
Intrinsic Value
Quality score
18/100
Best check: net debt, -$2M. Weakest: return on capital, -39.8%.
Quality
Dividend
None
No dividend in the company filings we hold.
Dividends
P/E
-2.06
Negative: a loss over the last twelve months. Price to free cash flow -2.41.
Financials

Questions about CytoMed Therapeutics

Is CytoMed Therapeutics (GDTC) overvalued?

At $0.77, CytoMed Therapeutics' price is 1231% above the $0.06 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is CytoMed Therapeutics' fair value?

Intrinsiqq's calculator puts CytoMed Therapeutics' fair value at $0.06 a share. It grows revenue per share 5% a year for 5 years, applies an exit P/S of 3.1, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.04. Every input can be changed on the Intrinsic Value tab.

Is CytoMed Therapeutics a high-quality business?

CytoMed Therapeutics scores 18 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from company filings. Its best check is net debt at -$2M, and its weakest is return on capital at -39.8%. The Quality tab shows every check against its target.

Does CytoMed Therapeutics (GDTC) pay a dividend?

No. CytoMed Therapeutics (GDTC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: company filings. Price: last close 16 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing GDTC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.